Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 62 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 62 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, 19107

pharmakonpress[at]pharmakonpress[.]gr

            2. Kaye D.M., Krum H.: Drug discovery for heart failure: a new era or the end of the pipeline? Nat. Rev. Drug Disc. 6: 127-139 (2007)

            3. Weber K.T.: Aldosterone in congestive heart failure. N. Engl. J. Med. 345: 1689-1697 (2001)

            4. Connell J.M., Davies E.: The new biology of aldosterone. J. Endocrinol. 186: 1-20 (2005)

            5. Marney A.M., Brown: Aldosterone and end-organ damage. Clin. Sci. (Lond.)  113: 267-278 (2007)

            6. Zhao W., et al.: ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am. J. Physiol. Heart Circ. Physiol. 291: H336-H343 (2006)

            7. Swedberg K., et al.:  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circ. 82: 1730-1736 (1990)

            8. Rouleau J.L., et al.: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol. 24: 583-591 (1994)

            9. Pitt B., et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341: 709-717 (1999)

            10. Pitt B., et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348: 1309-1321 (2003)

            11. Rousseau M.F., et al.: Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J. Am. Coll. Cardiol. 40: 1596-1601 (2002)

            12. Ganguly A., Davis J.S.: Role of calcium and other mediators in aldosterone secretion from the adrenal glomerulosa cells. Pharmacol. Rev. 46: 417-447 (1994)

            13. De Gasparo M., et al.: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52: 415-472 (2000)

            14. Lefkowitz R.J., et al.: New roles for β-arrestins in cell signaling: Not just for seven-transmembrane receptors. Mol. Cell 24: 643-652 (2006)

            15. Lefkowitz R.J., Shenoy S.K.: Transduction of Receptor Signals by β-Arrestins. Science 308, 512-517 (2005). 

            16. Lymperopoulos, A. et al. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13: 315-323 (2007)

            17. Rainey W.E., et al.: Adrenocortical cell lines. Mol. Cell. Endocrinol. 228: 23-38 (2004)

            18. Bird I.M., et al.: Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinol. 133: 1555-1561 (1993)

            19. Lymperopoulos A., et al.: Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol. Ther. 16: 302-307 (2008)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr